Premature Ejaculation Treatment Market Necessity And Demand 2018 to 2026 With top Key Players Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Absorption Pharmaceuticals, Ampio Pharmaceuticals

The global premature ejaculation treatment market size was valued at US$ 1.5 Bn in 2017, and is expected to witness a CAGR of 8.7% over the forecast period (2018 – 2026). Premature ejaculation also called as rapid ejaculation, premature climax or early ejaculation. It is a disorder, which causes early ejaculation of semen during sexual intercourse. Premature ejaculation is a very common problem, and its exact cause is not known. However, causes include early sexual experiences, sexual abuse, poor body image, depression, anxiety, abnormal hormone levels, inherited traits, inflammation and infection of the prostate or urethra, and worrying about premature ejaculation.

Get The PDF Brochure @ https://www.coherentmarketinsights.com/insight/request-pdf/1956

Market Dynamics

Increasing launches of novel products for the treatment of premature ejaculation is expected to fuel the global premature ejaculation treatment market growth. For instance, in 2016, Regent Pacific Group Limited, a Hong Kong-based investment group, launched its product, Fortacin in the U.K. Fortacin is a topical spray, which contains low doses of two anesthetics - lidocaine and prilocaine and is indicated for the treatment of premature ejaculation. Furthermore, increasing prevalence of premature ejaculation due to unhealthy lifestyle and various factors such as depression and hormonal imbalance is expected to rise demand for premature ejaculation treatment drugs. For instance, according to the data published by National Center for BioDrug Type Information in 2016, around 25.8% of male in China are suffering from premature ejaculation.

Frequent launches and approvals of novel premature ejaculation treatment products is expected to drive growth of the market

Key players in the market are focusing on launching new products, which in turn is expected to aid in growth of the market. For instance, in 2012, Absorption Pharmaceuticals, LLC launched its Promescent, an over-the-counter lidocaine-based spray, indicated for premature ejaculation. Furthermore, in 2013, Absorption Pharmaceuticals, LLC received patent for its Promescent, for premature ejaculation (PE) from the U.S. Patent and Trademark Office. The launches of novel drugs, which are indicated for the treatment of premature ejaculation is expected to fuel growth of the global premature ejaculation treatment market in the near future.

Increasing strategic collaborations for development of new diagnostic tools is expected to propel the market growth

Key players in the market are involved in strategic collaborations for the development of premature ejaculation treatment drugs. For instance, in 2012, Ampio Pharmaceuticals, Inc. entered in a strategic agreement with Ethypharm S.A. for the manufacturing of Zertane, Ampio's drug indicated for the treatment of premature ejaculation. In 2013, Absorption Pharmaceuticals LLC entered into a strategic collaboration with Kaiser Permanente for initiating clinical trial to evaluate the efficacy of Promescent lidocaine spray for men with premature ejaculation (PE). Such strategic collaborations by key players for the development, manufacturing, and evaluation of novel drugs is expected to fuel the global premature ejaculation treatment market growth.

Key players operating in the premature ejaculation treatment market include Regent Pacific Group Limited, Menarini Group, Furiex Pharmaceuticals, Inc., Absorption Pharmaceuticals, LLC, Ampio Pharmaceuticals, Inc., Aytu BioScience, NeuroHealing Pharmaceuticals Inc., and Dong-A Pharmaceutical Co., Ltd.

Request for Customization @ https://www.coherentmarketinsights.com/insight/request-customization/1956

Increasing prevalence of premature ejaculation is expected to increase demand for premature ejaculation drugs. For instance, according to the data published by European Association of Urology in 2017, the prevalence rate of premature ejaculation in the U.S. was estimated to be 30% (18-29 years), 32% (30-39 years), 28% (40-49 years), and 55% (50-59 years). According to the same source, the prevalence rate of four sub-types of erectile dysfunction was were 2.3% (lifelong PE), 3.9% (acquired PE), 8.5% (natural variable PE), and 5.1% (premature-like ejaculatory dysfunction). Such high prevalence of premature ejaculation is expected to lead to high demand for its treatment drugs and drive premature ejaculation treatment market growth.

Launch of alternative treatment methods for premature ejaculation is expected to be a major factor, which can restrain the market growth. For instance, in May 2018, InnovaDerma PLC launched a device, Prolong. Prolong is a FDA approved device used in the treatment of premature ejaculation. Launches of such devices is expected to restrain growth of the global premature ejaculation treatment market

Contact Us:

Mr. Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email: sales@coherentmarketinsights.com

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

This release was published on openPR.